Roche

News

Roche claims US approval for lymphoma bispecific Lunsumio

The FDA has given a green light to Roche's CD20xCD3 bispecific antibody Lunsumio as a treatment for relapsed or refractory follicular lymphoma, following the lead of the European Commission

News

NICE backs use of Boehringer's Ofev in IPF from diagnosis

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess

News

ASH: CD20 bispecific antibodies take centre stage in lymphom...

As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with n

News

Roche's head of pharma Bill Anderson heads for exit

Roche announced this morning that its head of pharmaceuticals, Bill Anderson, is leaving the company to pursue "other opportunities" after four years in the role.

News

Genentech withdraws US indication of Tecentriq for bladder, ...

Genentech, a

News

Genomic testing 'should be offered to all cancer patients in...

A group representing pharma companies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targ

Roche claims US approval for lymphoma bispecific Lunsumio

NICE backs use of Boehringer's Ofev in IPF from diagnosis

ASH: CD20 bispecific antibodies take centre stage in lymphom...

Roche's head of pharma Bill Anderson heads for exit

Genentech withdraws US indication of Tecentriq for bladder, ...

Genomic testing 'should be offered to all cancer patients in...

CEPI steps in to fund Moderna's pandemic flu jab

How to meet your physicians where they are online

Roche

Editor's Picks